(19) World Intellectual Property Organization

International Bureau





(43) International Publication Date 17 March 2005 (17.03.2005)

PCT

(10) International Publication Number WO 2005/023833 A3

- (51) International Patent Classification⁷: C12N 9/02, C07K 14/47, 16/18, G01N 33/68, A61K 38/17, C12N 15/12
- (21) International Application Number:

PCT/EP2004/009771

(22) International Filing Date:

2 September 2004 (02.09.2004)

(25) Filing Language:

English

(26) Publication Language:

English


(30) Priority Data:

,	I Hority Data.	•	
	03019642.2	5 September 2003 (05.09.2003)	EP
	PCT/EP03/013980		
		10 December 2003 (10.12.2003)	EP
	04001895.4	29 January 2004 (29.01.2004)	EP
	04001894.7	29 January 2004 (29.01.2004)	EP
	04007447.8	26 March 2004 (26.03.2004)	EP
	PCT/EP04/004891	7 May 2004 (07.05.2004)	EP
٠.	PCT/EP04/004889	7 May 2004 (07.05.2004)	EP
	04018874.0	9 August 2004 (09.08.2004)	EP

- (71) Applicant (for all designated States except US): CELL-ZOME AG [DE/DE]; Meyerhofstrasse 1, 69117 Heidelberg (DE).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): HOPF, Carsten [DE/DE]; Nietzschestrasse 30, 68165 Mannheim (DE).
- (74) Agent: HUHN, Michael; Isenbruck, Bösl, Hörschler, Wichmann, Huhn, Theodor-Heuss-Anlage 12, 68165 Mannheim (DE).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,

[Continued on next page]

(54) Title: TREATMENT OF NEURODEGENERATIVE DISEASES



(57) Abstract: The present invention relates to the uses of FADS2 interacting molecules, especially FADS2 inhibitors, for the preparation of a medicament for the treatment of neurodegenerative diseases, specially Alzheimer's disease.



2005/023833 A3 |||||||||||

WO 2005/023833 A3



ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
23 June 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.